References
- 1. Einhäupl K, Bousser MG, de Bruijn SF et al. (2006). EFNS guideline on the treatment of cerebral venous and sinus thrombosis. Eur J Neurol. 13 (6), 553–9.
- 2. deVeber G, Andrew M, Adams C et al. (2001). Cerebral sinovenous thrombosis in children. N Engl J Med. 345 (6), 417–23.
- 3. Wysokinska EM, Wysokinski WE, Brown RD et al. (2008). Thrombophilia differences in cerebral venous sinus and lower extremity deep venous thrombosis. Neurology. 19;70(8), 627-33.
- 4. Saadatnia M, Salehi M, Movahedian A et al (2015). Factor V Leiden, factor V Cambridge, factor II GA20210, and methylenetetrahydrofolate reductase in cerebral venous and sinus thrombosis: A case-control study. J Res Med Sci. 20 (6), 554–562.
- 5. Countinho JM, Ferro JM, Canhão P et al. (2009). Cerebral Venous and Sinus Thrombosis in Women. Stroke. 40(7), 2356-2361.
- 6. Flores-Barragan JM, Hernandez-Gonzalez A, Gallardo-Alcaniz MJ et al. (2009). Clinical and therapeutic heterogeneity of cerebral venous thrombosis: a description of a series of 20 cases. Rev Neurol. 49(11), 573-6.
- 7. Purvin VA, Trobe JD, Kosmorsky G. (1995). Neuroophthalmic features of cerebral venous obstruction. Arch Neurol. 52(9), 880–885.
- 8. Ferro JM, Canhão P, Bousser MG et al. (2008). Early seizures in cerebral vein and dural sinus thrombosis: risk factors and role of antiepileptics. Stroke. 39(4), 1152–1158.
- 9. Alvis-Miranda HR, Milena Castellar-Leones S, Alcala-Cerra G et al. (2013). Cerebral sinus venous thrombosis. J Neurosci Rural Pract. 4(4), 427-438.
- 10. Mehta R, Shapiro AD. (2008). Plasminogen activator inhibitor type 1 deficiency. Haemophilia. 14(6), 1255-60.
- 11. Lee C.C, Tze-Sing H. (2005). Plasminogen Activator Inhibitor-1: The Expression, Biological Functions, and Effects on Tumorigenesis and Tumor Cell Adhesion and Migration. J Cancer Mol. 1(1), 25-36.
- 12. Yasar Yildiz S, Kuru P, ToksoyOner E et al. (2014). Functional stability of plasminogen activator inhibitor-1. Scientific World Journal. 2014:858293.
- 13. Đorđević V, Gvozdenov M, Pruner I et al. (2013). Učestalost PAI-1 4G/5Ggenske varijante u srpskoj populaciji. Medicinski glasnik Specijalna bolnica za bolesti štitaste žlezde I bolesti metabolizma Zlatibor. 18 (49), 28-41.
- 14. Zhang H, Dong P, Yang X et al. (2014). Plasminogen activator inhibitor-1 4G/5G polymorphism is associated with coronary artery disease risk: a meta-analysis. Int J ClinExp Med. 7(10), 3777-3788.
- 15. Parpugga TK, Tatarunas V, Skipskis V et al (2015). The Effect of PAI-1 4G/5G Polymorphism and Clinical Factors on Coronary Artery Occlusion in Myocardial Infarction. Dis Markers. 2015:260101.
- 16. Wang J, Wang C, Chen N et al. (2014). Association between the plasminogen activator inhibitor-1 4G/5G polymorphism and risk of venous thromboembolism: a meta-analysis. Thromb Res. 134(6), 1241-8.
- 17. Gohil R, Peck G, Sharma P. (2009). The genetics of venous thromboembolism. A meta-analysis involving approximately 120,000 cases and 180,000 controls. Thromb Haemost. 102(2), 360-70.
- 18. Doggen CJ, Bertina RM, Cats VM et al. (1999). The 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene is not associated with myocardial infarction. Thromb Haemost. 82(1), 115-20.
- 19. Chen YL, Zhang JX, Wang PX et al. (2005). Association of 4G/5G polymorphism in PAI1 promoter with PAI1 level in deep vein thrombosis. Zhonghua Yi Xue Yi ChuanXue Za Zhi. 22(6), 624-7.
- 20. Tsantes AE, Nikolopoulos GK, Bagos PG et al. (2007). Plasminogen activator inhibitor-1 4G/5G polymorphism and risk of ischemic stroke: a meta-analysis. Blood Coagul Fibrinolysis. 18(5), 497-504.
- 21. Bentley P, Peck G, Smeeth L et al. (2010). Causal Relationship of Susceptibility Genes to Ischemic Stroke: Comparison to Ischemic Heart Disease and Biochemical Determinants. PLoS ONE. 5(2), e9136.
- 22. Ringelstein M, Jung A, Berger K et al. (2012). Promotor polymorphisms of plasminogen activator inhibitor-1 and other thrombophilic genotypes in cerebral venous thrombosis: a case-control study in adults. J Neurol. 259(11), 2287-92.
- 23. Xu F, Liu H, Sun Y. (2016). Association of plasminogen activator inhibitor-1 gene polymorphism and type 2 diabetic nephropathy. Ren Fail. 38(1), 157-62.
- 24. Xu K, Liu X, Yang F et al. (2013). PAI-1-675 4G/5G polymorphism in association with diabetes and diabetic complications susceptibility: a meta-analysis study. PLoS One. 8(11), e79150.
- 25. Li X, Liu Y, Zhang R et al. (2015). Meta-analysis of the association between plasminogen activator inhibitor-1 4G/5G polymorphism and recurrent pregnancy loss. Med SciMonit. 21, 1051-6.
- 26. Morgan JA, Bombell S, McGuire W. (2013). Association of plasminogen activator inhibitor-type 1 (-675 4G/5G) polymorphism with pre-eclampsia: systematic review. PLoS One. 8(2), e56907.
- 27. Lee YH, Song GG. (2014). Plasminogen activator inhibitor-1 4G/5G and the MTHFR 677C/T polymorphisms and susceptibility to polycystic ovary syndrome: a meta-analysis. Eur J Obstet Gynecol Reprod Biol. 175:8-14.
- 28. Nie W, Li B, Xiu QY. (2012). The -675 4G/5G polymorphism in plasminogen activator inhibitor-1 gene is associated with risk of asthma: a meta-analysis. PLoS One. 7(3), e34385.
- 29. Li L, Nie W, Zhou H et al. (2013). Association between plasminogen activator inhibitor-1-675 4G/5G polymorphism and sepsis: a meta-analysis. PLoS One. 8(1), e54883.
- 30. Reshetniak TM, Ostriakova EV, Patrusheva NL et al. (2013). Plasminogen activator inhibitor type 1 gene polymorphism and thromboses in patients with antiphospholipid syndrome. TerArkh. 85(1), 76-84.